0
0
May 16, 2025 – In a significant advancement for migraine sufferers, the U.S. Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ new self-administered treatment, Brekiya. This innovative medication offers a convenient and rapid option for adults experiencing acute migraine attacks or cluster headaches.
A New Option for Migraine Relief
Brekiya delivers a single dose of dihydroergotamine mesylate via an autoinjector, allowing patients to manage their symptoms quickly and independently. Unlike some existing treatments, Brekiya does not require refrigeration or device assembly, and can be injected directly into the mid-thigh. This ease of use is expected to be particularly beneficial for patients who need fast relief and may not respond well to oral medications.
Migraines are characterized by intense, pulsating pain, often on one side of the head, and are frequently accompanied by nausea, vomiting, and sensitivity to light. Cluster headaches, another approved indication for Brekiya, are known for their severe, unilateral pain.
Addressing Unmet Needs
Amneal Pharmaceuticals emphasized that Brekiya fills a critical gap for patients who have not found relief with oral therapies. Current oral treatments on the market include Symbravo, recently approved by Axsome Therapeutics, and Nurtec ODT from Pfizer. Pfizer also offers Zavzpret, a nasal spray for acute migraine attacks.
Path to Approval
The FDA’s approval follows an earlier rejection due to issues at a third-party manufacturing site. Amneal responded by relocating production to its own facility, paving the way for this week’s regulatory green light.
Brekiya is expected to become available in the United States in the second half of 2025. Pricing details will be announced closer to the product’s launch.
Disclaimer:
This article is based on information reported by Reuters on May 15, 2025, and official announcements from Amneal Pharmaceuticals. It is intended for informational purposes only and should not be construed as medical advice. For personalized medical recommendations, please consult a healthcare professional.
Citations:
